children with pulmonary hypertension
Conditions
Interventions
Trade Name: Propofol
Product Name: propofol
Pharmaceutical Form: Intravenous infusion
Trade Name: Isoflurane
Product Name: isoflurane
Pharmaceutical Form: Inhalation vapour*
Sponsors
University Hospitals Bristol
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All children between 3 months and 16 years of age with pulmonary arterial hypertension undergoing a PVR study Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Children with a known reaction to oneof the study drugs eg malignant hyperpyrexia or a disorder of fatty acid oxidation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: WE hypothesise that there is no difference between the effects of isoflurane and propofol anaesthesia on pulmonary vascular resistance (PVR). Therefore the primary objective of this trial is is to evaluate the equivalaence of the physiological effects of two anaesthetics drugs (propofol and isoflurane) on PVR in children with pulmonary hypertension.;Secondary Objective: To evaluate the physiological effects on systemic vascular resistance;Primary end point(s): Percentage change in PVR under propofol anaesthesia compared with isoflurane anaesthesia | — |
Countries
United Kingdom
Outcome results
None listed